7 results about "Chlorambucil" patented technology

This invention provides a chlorambucil NO donor prodrug having the structure shown in Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). It involves reacting chlorambucil with a dihaloalkane to obtain a halochlorambucil intermediate; reacting the halochlorambucil intermediate with silver nitrate to obtain the chlorambucil NO donor prodrug. This invention applies the chlorambucil NO donor prodrug to the preparation of drugs for treating tumors, such as melanoma, lymphoma, leukemia, or breast cancer. This nanosystem exhibits good NO release levels under light irradiation. Cellular experiments have demonstrated its good antitumor effect, providing a new strategy for multimodal combined antitumor therapy.

This invention discloses a class of enzyme-activated prodrug compounds having the following general structural formula I: This invention discloses a class of enzyme-sensitive chlorambucil analog prodrugs. These prodrugs exhibit high selectivity for hypoxic tumors and can be effectively activated within hypoxic tumor cells. Upon specific activation, the prodrug releases free chemotherapeutic drug chlorambucil, simultaneously releasing the photosensitizer cyanine dye, achieving an "OFF-ON" photosensitivity conversion, and generating a large number of reactive oxygen species, thus achieving the unification and synergy of photodynamic therapy and activatable chemotherapy.

The application provides imidazotetrazine compounds or pharmaceutically acceptable salts thereof, and a preparation method and application thereof, and belongs to the technical field of medicines. The imidazotetrazine compounds or pharmaceutically acceptable salts thereof are obtained by connecting valproic acid, chlorambucil and borneol to an imidazotetrazine group through an ester bond or an amide bond by using a splicing principle. The imidazotetrazine compounds or pharmaceutically acceptable salts thereof have better antitumor activity, and a new generation of powerful antitumor drugs can be developed.

The invention discloses an eudecane type sesquiterpene lactone TBB chlorambucil heterocomplex and application thereof, the derivative is a compound TBB-DJ, and the structural formula of the derivative is as shown in the formula TBB-DJ. Experimental results show that the compound TBB-DJ has a remarkable inhibition effect on proliferation activity and migration ability of liver cancer cells, and shows a unique anti-hepatocellular carcinoma effect of the compound TBB-DJ. Therefore, the compound TBB-DJ has an important application prospect in research and development of anti-hepatocellular carcinoma drugs.

This invention belongs to the field of nanomedicine delivery systems, specifically relating to a dual-sensitivity co-loaded emodin and chlorambucil micelles, their preparation method, and applications. The polymer structure is as follows: Using polymethacrylate as the linking unit, this invention designs and synthesizes a dendritic polymer p(mPEG-co-HPBE-co-EMD) grafted with polyethylene glycol monomethyl ether, p-hydroxymethylphenylboronic acid pinacol ester, and emodin, and uses it for encapsulating chlorambucil. This co-loaded polymer micelle can be used for the co-delivery of emodin and chlorambucil. This co-loaded micelle improves the water solubility of the drug, has a suitable particle size, and dual ROS / pH sensitivity, enabling targeted release of emodin and chlorambucil at tumor sites, achieving synergistic treatment with chemotherapy and oxidative therapy. In the formula, n = 30-85, x:y:z = 1:2-5:1-3.

The invention belongs to the field of biological medicines, and provides a preparation method and application of a stapled peptide and micromolecular antitumor drug covalent conjugate with high stability and strong antitumor activity. Traditional micromolecular antitumor drugs such as camptothecin, chlorambucil and the like have the problems of low water solubility, low bioavailability, poor stability, drug resistance and the like. The camptothecin or chlorambucil is covalently coupled with the stapled peptide through AEA, so that the water solubility of the small molecule medicine is remarkably improved, the anti-tumor onset time is remarkably shortened, and the long-lasting tumor cell proliferation inhibition capability is shown. Compared with linear peptide, the stability of the stapled peptide is remarkably improved, and a polypeptide drug coupling strategy based on the stapled peptide solves the problem of poor stability of polypeptide in a coupled drug on one hand, and provides a new thought for further development of classical anti-tumor drugs on the other hand.

The invention relates to application of chlorambucil in prevention and control and growth promotion of panax notoginseng diseases. It is found that chlorambucil has a good pseudo-ginseng rust rot fungus inhibiting effect and a good growth promoting effect on beneficial bacteria such as mortierella and trichoderma and can be used for promoting growth of pseudo-ginseng, and therefore chlorambucil can be widely applied to pseudo-ginseng disease control and growth promoting.